Hideo Yoshida

Hideo Yoshida

Auto-generated profile, based on publicly available information

Hideo Yoshida

Graduate School of Horticulture, Chiba University, Matsudo, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Frontiers in Plant Science
Verified
Journal Article
Open access
XKXinglin Ke
Xinglin Ke
HYHideo Yoshida
Hideo Yoshida
SHShoko Hikosaka
Shoko Hikosaka
EGEiji Goto
Eiji Goto
This study aimed to analyze the effects of photosynthetic photon flux density (PPFD) on fruit biomass radiation-use efficiency (FBRUE) of the dwarf tomato cultivar ‘Micro-Tom’ and to determine the suitable PPFD for enhancing the FBRUE under LED light at the reproductive growth stage. We performed four PPFD treatments under white LED light: 200, 300, 500, and 700 μmol m−2 s−1. The results demonstrated that a higher PPFD led to higher fresh and dry weights of the plants and lowered specific leaf areas. FBRUE and radiation-use efficiency (RUE) were the highest under 300 μmol m−2 s−1. FBRUE decreased by 37.7% because RUE decreased by 25% and the fraction of dry mass portioned to fruits decreased by 16.9% when PPFD increased from 300 to 700 μmol m−2 s−1. Higher PPFD (500 and 700 μmol m−2 s−1) led to lower RUE owing to lower light absorptance, photosynthetic quantum yield, and photosynthetic capacity of the leaves. High source strength and low fruit sink strength at the late reproductive growth stage led to a low fraction of dry mass portioned to fruits. In conclusion, 300 µmol m−2 s−1 PPFD is recommended for ‘Micro-Tom’ cultivation to improve the FBRUE at the reproductive growth stage.

1 January 1999 in Hypertension Research
Verified
Journal Article
Open access
PDF file
YKYutaka Kimura
Yutaka Kimura
HTHirofumi Tomiyama
Hirofumi Tomiyama
ENEisuke Nishikawa
Eisuke Nishikawa
GWGohki Watanabe
Gohki Watanabe
KSKohichiro Shiojima
Kohichiro Shiojima
NDNobutaka Doba
Nobutaka Doba
A cross-sectional study was conducted to compare the morphological and functional characteristics of the cardiovascular system among subgroups of hypertension defined by the JNC-VI recommendations. One hundred and sixteen subjects (normotensives and unmedicated hypertensives: 49±10 yr) were classified into 4 groups based on the criteria of JNC-VI: normotensive (NOR: n=38), high-normal blood pressure (HN: n=16), stage 1 hypertensive (SI: n=28), and stage 2 to 3 hypertensive (SII-III: n=34). Ultrasonographic examinations of the heart and carotid artery were performed in all subjects, and the following parameters were obtained: left ventricular mass index (LVMI), relative wall thickness at end-diastole (RWTd), cardiac diastolic function (A/E), common carotid artery diameter (CAD), intimal media thickness of the common carotid artery (IMT), and distensibility of the common carotid artery (Distens). RWTd, A/E, and IMT in SI (RWTd, 0.41±0.07; A/E, 1.21±0.41; IMT, 0.69±0.17mm) and SII-III patients (0.40±0.08, 1.38±0.33, 0.80±0.21mm) were larger than those in NOR patients (0.33±0.03, 0.86±0.21, 0.56±0.10mm) (p<.01). Furthermore, LVMI in SII-III (135.5±35.5g/m2) patients was larger than that in NOR patients (99.4±17.5g/m2) (p<.05). RWTd in HN patients (0.37 ±0.06) was significantly higher than that in NOR patients (p<.05). A/E tended to be larger in HN than in NOR patients (p<0.1). In the normotensives, no significant difference in any of the parameters was detected between those with optimal (n=19) and normal (n=19) blood pressure. Thus, both morphological and functional changes were associated with elevation of blood pressure. Cardiac morphological adaptation and functional impairment were present even in subjects with high-normal blood pressure level, while there were no significant differences between the normal and optimal subsets. (Hypertens Res 1999; 22: 291-295)

20 June 2019 in Genesis
Verified
Journal Article
Closed access
PDF file
SOSachie Ono
Sachie Ono
TSTakeshi Saito
Takeshi Saito
KTKeita Terui
Keita Terui
HYHideo Yoshida
Hideo Yoshida
HEHideki Enomoto
Hideki Enomoto

23 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HYHideo Yoshida
Hideo Yoshida
YAYuka Ashikawa
Yuka Ashikawa
SIShinsuke Itoh
Shinsuke Itoh
TNTakashi Nakagawa
Takashi Nakagawa
AAAkimune Asanuma
Akimune Asanuma
HHHiroyoshi Hidaka
Hiroyoshi Hidaka
K-134 is a more potent antiplatelet drug with a selective inhibitory effect on phosphodiesterase 3 (PDE3) compared with its analogue, cilostazol. This study was performed to compare the ameliorating effects of K-134 and cilostazol on brain damage in an experimental photothrombotic cerebral infarction model. We investigated the effects of oral preadministration of PDE3 inhibitors in a rat stroke model established by photothrombotic middle cerebral artery (MCA) occlusion. K-134 significantly prolonged MCA occlusion time at doses >10 mg/kg, and reduced cerebral infarct size at 30 mg/kg in the stroke model (n = 12, 87.5±5.6 vs. 126.8±7.5 mm3, P<0.01), indicating its potent antithrombotic effect. On the other hand, the effects of cilostazol on MCA occlusion time and cerebral infarct size are relatively weak even at the high dosage of 300 mg/kg. Furthermore, K-134 blocked rat platelet aggregation more potently than cilostazol in vitro. Also in an arteriovenous shunt thrombosis model, K-134 showed an antithrombotic effect greater than cilostazol. These findings suggest that K-134, which has strong antithrombotic activity, is a promising drug for prevention of cerebral infarction associated with platelet hyperaggregability.

1 February 2022 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
HYHideo Yoshida
Hideo Yoshida
SIShinsuke Itoh
Shinsuke Itoh
FFFarhana Ferdousi
Farhana Ferdousi
HIHiroko Isoda
Hiroko Isoda
Post-stroke antiplatelet therapy has been proved to reduce the risk of recurrent stroke; however, it may also increase the incidence of intracranial hemorrhage that could offset any benefits. Therefore, the balance between the benefits and risks of antiplatelet drugs is a critical issue to consider. In the present study, we have compared the effects of post-stroke administration of antiplatelet agents on functional outcomes in the stroke-prone spontaneously hypertensive rat (SHRSP), an established animal model that mimics human lacunar stroke and cerebral small vessel disease. We confirmed that a potent phosphodiesterase 3 (PDE3) inhibitor, K-134, significantly improved post-stroke survival rate and survival time, attenuated stroke-induced neurological deficits, and decreased the incidence of cerebral lesion caused by intracerebral hemorrhage and softening. Similarly, cilostazol showed beneficial effects, though to a lower extent with respect to the survival outcome and neurological symptoms. On the other hand, a P2Y12 inhibitor, clopidogrel significantly improved survival outcomes at the higher dose but caused massive bleeding in the brain at both low and high doses. In contrast, no hemorrhagic lesion was observed in K-134-treated SHRSPs despite its antiplatelet activity. Our findings indicate that K-134 may have a superior post-stroke therapeutic outcome in comparison to other antiplatelet drugs.